Wednesday, April 23, 2014 3:08:51 PM
Wound Management Technologies Growth Continues with Record Sales for First Quarter 2014 Following a Strong 2013 Year End
Apr 22, 2014 (ACCESSWIRE via COMTEX) -- ADDISON, TX / ACCESSWIRE / April 22, 2014 / Wound Management Technologies, Inc., (OTCQB: WNDM) announced revenues of nearly $700,000 for the first quarter of 2014, a gain of 82% over the first quarter of 2013. Approximately 80% of revenues were from the CellerateRX(R) product line and the other 20% of revenue occurred in the Resorbable Orthopedic Products, LLC subsidiary (ROP). The CellerateRX first quarter revenues included sales to 65 new accounts mixed between the wound care and surgical product lines. "Our growth mirrors the results we anticipated in our three year strategic plan and we are excited about the organic growth that is occurring," stated Robert Lutz, Jr., Chairman and CEO. "This is the strongest quarter ever for CellerateRX sales. ROP's revenues were from license fees and now we will begin collecting royalty income from this license. Our team is collectively doing a great job of meeting our goals."
The Company also wants to share its Letter from the CEO, published in the 2013 10-K:
LETTER FROM THE CEO - GROWTH AND LOOKING TO THE FUTURE
Dear Shareholders:
2013 continued to be a year of transition and by year end we were able to shift our focus firmly to the future instead of dealing with the various issues of the past. We ended the year with the announcement on December 18th that existing shareholders committed to invest an additional $2.4M in the company in Series C preferred shares and to convert over $1.5M of existing debt into the Series C. This funding, along with the $1.2M invested by Brookhaven Medical, is allowing us to focus on business growth as we now have ample funding in place to fulfill the next stages of our strategic plan.
We continue to execute on this plan, ending the year with revenues of $1,726,392, showing a growth of $552,848 or 47.1% over 2012 respectively. Importantly, we are beginning to realize revenue from our new initiatives in CellerateRX Surgical and from our resorbable hemostat in addition to our CellerateRX wound care sales. 2014 will continue to show growth in all three areas as well as in new marketing areas that we will announce during the year.
An enormous benefit of the recent investments is that they allowed us to expand our executive team in order to capitalize on our market opportunities. Now in March 2014 we are enjoying the efforts of new staff including Deborah Hutchinson as President, Darren Stine as Chief Financial Officer, Jen Taylor as Director of Marketing and Business Development, Jane Fore, MD as Chief Medical Officer, Dr. Alec Hochstein as our new Medical Director, and Barry Constantine as Director of Research and Development. They join Ken Snider who became our EVP of Sales last September. This multi-talented group added to our existing team allows us to both promote our current products and to also work on developing additional products and marketing strategies.
Our relationship with WellDyne Health has continued to strengthen culminating in September 2013 in the formalization of a three-year Marketing Services and Shipping Agreement for the CellerateRX wound care and surgical product lines. Together we are exploring those and other new marketing programs and segments for our products. We are also working on many key international opportunities for both our CellerateRX wound care and surgical products and our resorbable hemostat.
Our CellerateRX distribution network continues to expand and grow, leading to exciting new account growth each month. Our distributors are a seasoned network of organizations and representatives that represent our products in a wide range of healthcare settings from surgical sites, to podiatry offices, to home care and beyond. They are bolstered by the remarkable results that the CellerateRX products continue to show, exciting our customers and giving us increased opportunities. That coupled with our increased participation in industry trade shows and meetings is helping us meet or exceed our sales goals each month.
In February we announced the FDA approval for an exciting new product that licenses technology from our Resorbable Orthopedic Products subsidiary, followed by our issuance of a Commercial License to BioStructures that gives us a new royalty revenue stream. This is the first of many exciting new announcements for this subsidiary.
In closing, I am enthusiastic about the road ahead for Wound Management and we look forward to sharing our progress with you in the months ahead.
Robert Lutz, Jr.
Chief Executive Officer
About Wound Management
Wound Management Technologies, Inc., is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management's primary focus is the distribution of its unique, patented collagen product, CellerateRX(R), which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable hemostat that is in the late stages of development. More information can be found on the company's web sites: www.wmgtech.com and www.celleraterx.com .
I invest in companies that I think will make me money. And everything I say is just my opinion.
Recent SMTI News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 08:09:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 01:20:18 PM
- Sanara MedTech Inc. Announces First Quarter 2024 Results • GlobeNewswire Inc. • 05/13/2024 01:15:00 PM
- Sanara MedTech Inc. Announces First Quarter Earnings Release and Conference Call Dates • GlobeNewswire Inc. • 04/29/2024 01:15:00 PM
- Sanara MedTech Inc. Announces $55 Million Debt Facility • GlobeNewswire Inc. • 04/18/2024 01:15:00 PM
- Sanara MedTech Inc. Announces the Appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer • GlobeNewswire Inc. • 04/05/2024 01:00:00 PM
- Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results • GlobeNewswire Inc. • 03/25/2024 08:05:00 PM
- Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release and Conference Call Dates • GlobeNewswire Inc. • 03/13/2024 01:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 08:05:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 08:05:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 11:20:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 11:18:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:01:46 PM
- Sanara MedTech Inc. Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2023 • GlobeNewswire Inc. • 02/22/2024 02:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:29:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:27:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:05:58 PM
- Sanara MedTech Inc. Announces Exclusive License Agreement for Patented Collagen Peptides • GlobeNewswire Inc. • 01/03/2024 02:15:00 PM
- Sanara MedTech Inc. Announces the Publication of a 5,335 Patient Study Demonstrating a Significant Reduction in Surgical Site Infections When Activated Collagen (CellerateRX® Surgical Powder) Was Used to Promote Wound Healing • GlobeNewswire Inc. • 11/30/2023 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:42:17 PM
- Sanara MedTech Inc. Announces Third Quarter 2023 Results • GlobeNewswire Inc. • 11/13/2023 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:02:43 PM
- Sanara MedTech Inc. Announces Third Quarter Earnings Release and Conference Call Dates • GlobeNewswire Inc. • 10/30/2023 01:15:00 PM
- Sanara MedTech Announces First Sale of ALLOCYTE® Plus Advanced Viable Bone Matrix and Provides Other Product Updates • GlobeNewswire Inc. • 10/10/2023 01:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/22/2023 08:05:32 PM
FEATURED POET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems • May 14, 2024 10:09 AM
FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM
VAYK Added New Manager for Expansion into $64 Billion Domestic Short-term Rental Market • VAYK • May 14, 2024 9:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM